RecruitingNot ApplicableNCT05174351
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
Effect of Beta-blocker Discontinuation on Functional Capacity and Cardiac Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction
Sponsor
UConn Health
Enrollment
30 participants
Start Date
Dec 20, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.
Eligibility
Min Age: 50 YearsMax Age: 80 Years
Inclusion Criteria6
- Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100
- N=30 (Target: 30).
- Age: 50 \~ 80 years.
- ECHO evidence of EF ≥50% and Grade 2 or 3 diastolic dysfunction.
- Chronic loop diuretic use
- Currently on beta-blocker
Exclusion Criteria4
- Beta blocker was prescribed for treating other cardiac conditions such as atrial fibrillation or coronary artery disease.
- Heart rate \> 100 bpm
- Recent hospitalization due to HF within 3 months
- Non-English speaker
Interventions
OTHERbeta blocker discontinuation
beta blocker discontinuation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05174351
Related Trials
Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System
NCT042377011 location
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459564 locations
A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD
NCT070935281 location
Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
NCT049457071 location
Transitions of Care Clinic (TOCC)
NCT069378271 location